BIOMAT Database Logo BIOMAT Database Logo

Decreased level of beta-endorphin-like immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type. 1983

H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba

beta-Endorphin-like immunoreactivity in cerebrospinal fluid(CSF) was observed to decrease in patients with Huntington's disease and dementia due to brain vascular disease. The greatest decrease was seen in patients with presenile and senile dementia of Alzheimer type(SDAT). The immunoreactivity significantly correlated with psychological functions when examined using a dementia rating scale (r=0.51, p less than 0.01, for all dementia, r=0.65, p less than 0.02, for only SDAT). These results suggest that a B-endorphin-like substance may be related in the pathophysiology of dementia.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002561 Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others. Brain Vascular Disorders,Intracranial Vascular Disorders,Vascular Diseases, Intracranial,Cerebrovascular Diseases,Cerebrovascular Insufficiency,Cerebrovascular Occlusion,Brain Vascular Disorder,Cerebrovascular Disease,Cerebrovascular Disorder,Cerebrovascular Insufficiencies,Cerebrovascular Occlusions,Disease, Cerebrovascular,Diseases, Cerebrovascular,Insufficiencies, Cerebrovascular,Insufficiency, Cerebrovascular,Intracranial Vascular Disease,Intracranial Vascular Diseases,Intracranial Vascular Disorder,Occlusion, Cerebrovascular,Occlusions, Cerebrovascular,Vascular Disease, Intracranial,Vascular Disorder, Brain,Vascular Disorder, Intracranial,Vascular Disorders, Brain,Vascular Disorders, Intracranial
D003704 Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. Senile Paranoid Dementia,Amentia,Familial Dementia,Amentias,Dementia, Familial,Dementias,Dementias, Familial,Dementias, Senile Paranoid,Familial Dementias,Paranoid Dementia, Senile,Paranoid Dementias, Senile,Senile Paranoid Dementias
D004723 Endorphins One of the three major groups of endogenous opioid peptides. They are large peptides derived from the PRO-OPIOMELANOCORTIN precursor. The known members of this group are alpha-, beta-, and gamma-endorphin. The term endorphin is also sometimes used to refer to all opioid peptides, but the narrower sense is used here; OPIOID PEPTIDES is used for the broader group. Endorphin
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006816 Huntington Disease A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4) Huntington Chorea,Juvenile Huntington Disease,Akinetic-Rigid Variant of Huntington Disease,Chorea, Chronic Progressive Hereditary (Huntington),Chronic Progressive Hereditary Chorea (Huntington),Huntington Chronic Progressive Hereditary Chorea,Huntington Disease, Akinetic-Rigid Variant,Huntington Disease, Juvenile,Huntington Disease, Juvenile-Onset,Huntington Disease, Late Onset,Huntington's Chorea,Huntington's Disease,Juvenile-Onset Huntington Disease,Late-Onset Huntington Disease,Progressive Chorea, Chronic Hereditary (Huntington),Progressive Chorea, Hereditary, Chronic (Huntington),Akinetic Rigid Variant of Huntington Disease,Chorea, Huntington,Chorea, Huntington's,Huntington Disease, Akinetic Rigid Variant,Huntington Disease, Juvenile Onset,Huntington Disease, Late-Onset,Juvenile Onset Huntington Disease,Late Onset Huntington Disease
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
Somatostatin-like immunoreactivity and acetylcholinesterase activities in cerebrospinal fluid of patients with Alzheimer disease and senile dementia of the Alzheimer type.
January 1986, Psychoneuroendocrinology,
H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type.
June 1997, Biological psychiatry,
H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia.
February 1995, Neuroscience letters,
H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
[Cerebrospinal fluid tau in senile dementia of Alzheimer type].
January 1995, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
Pancreastatin-like immunoreactivity of cerebrospinal fluid in patients with Alzheimer type dementia: evidence of aberrant processing of pancreastatin in Alzheimer type dementia.
August 1994, Neuroscience letters,
H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
October 1987, Brain : a journal of neurology,
H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
Acetylcholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
September 1981, Acta neurologica Scandinavica,
H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
Beta-endorphin-like immunoreactivity increases in cerebrospinal fluid of acute head-injured patients.
October 1988, Neuropeptides,
H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type.
January 1985, Annals of neurology,
H Kaiya, and T Tanaka, and K Takeuchi, and K Morita, and S Adachi, and H Shirakawa, and H Ueki, and M Namba
Peptide histidine methionine in cerebrospinal fluid of patients with senile dementia of the Alzheimer type.
March 1993, The Japanese journal of psychiatry and neurology,
Copied contents to your clipboard!